Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.3
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 19, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 31, 2019
Dec. 31, 2018
Accrued research and development expenses   $ 1,121,881   $ 1,121,881     $ 532,790
Research and development expense   1,158,757 $ 56,459 2,269,269 $ 165,997    
MD Anderson [Member]              
Accrued research and development expenses   507,316   507,316      
Promissiory note, principal amount           $ 250,000  
Research and development expense   $ 249,171   $ 1,230,441      
Amount payable for agreement $ 2,038,000